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Tracy Li h, Anil Londhe h, Parthiv Mahadevia h, Nicolas Girard i
a

University of California San Diego, San Diego, CA, USA
Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK
Instituto Oncológico Dr Rosell, Centro Médico Teknon, Grupo QuironSalud, Barcelona, Spain
d
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
e
University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA
f
Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI, USA
g
UGC Intercentros Oncol Med Hosp Univer Regional y Virgen Victoria, IBIMA, Malaga, Spain
h
Janssen Research & Development, Spring House, PA, USA
i
Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France
b
c

A R T I C L E I N F O

A B S T R A C T

Keywords:
Non-small cell lung cancer
Advanced lung cancer
EGFR mutations
EGFR exon 20 insertions
Flatiron registry

Introduction: Real-world clinical outcomes in patients with advanced NSCLC harboring EGFR exon 20 insertion
(exon20ins) mutations have not been extensively studied. We conducted a retrospective cohort study to assess the
clinical outcomes of EGFR exon20ins compared with common EGFR (cEGFR) mutations.
Methods: Adults with advanced NSCLC harboring any EGFR mutations in the NSCLC Flatiron registry (2011
through May 2020) were included. To compare the relative prognosis (prognostic value) of exon20ins vs cEGFR,
real-world overall survival (rwOS) was the primary endpoint. Separately, to compare the relative response to
tyrosine kinase inhibitor (TKI) treatment (predictive value), real-world progression-free survival (rwPFS) was the
primary endpoint.
Results: For the prognostic value analysis, 3014 patients with EGFR mutant NSCLC (cEGFR, n = 2833; EGFR
exon20ins, n = 181) were eligible. The median (95% CI) rwOS was 16.2 (11.04–19.38) months in the EGFR
exon20ins cohort vs 25.5 (24.48–27.04) months in the cEGFR cohort (adjusted HR, 1.75 [1.45–2.13]; p <
0.0001); 5-year rwOS was 8% and 19%, respectively. For the predictive value analysis, 2825 patients received
TKI treatment and were eligible (cEGFR, n = 2749; EGFR exon20ins, n = 76). The median (95% CI) rwPFS from
start of the first TKI was 2.9 (2.14–3.91) months in the EGFR exon20ins cohort vs 10.5 (10.05–10.94) months in
the cEGFR cohort (adjusted HR, 2.69 [2.05–3.54]; p < 0001). Among patients with EGFR exon20ins, the most
common prescribed first-line therapy was platinum-based chemotherapy (61.3%) followed by EGFR TKIs
(21.5%); second-line treatments were varied, with no clear standard of care.
Conclusions: Patients with EGFR exon20ins have poor prognosis and receive little benefit from EGFR TKI treat
ment. More effective therapies are needed in this difficult-to-treat population.

Abbreviations: cEGFR, common EGFR mutations; exon20ins, exon 20 insertion mutations; IO, immunotherapy; NOS, not otherwise specified; rwOS, real-world
overall survival; rwPFS, real-world progression-free survival; rwTTNT, real-world time to next therapy.
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1. Introduction

2. Methods

In patients with advanced NSCLC harboring exon 19 deletions or
L858R substitution mutations in the epidermal growth factor receptor
(EGFR) gene, treatment with EGFR tyrosine kinase inhibitors (TKIs) has
demonstrated improvement in progression-free survival (PFS)[1–5] and
overall survival (OS)[6] compared with chemotherapy. These 2 muta
tion types, referred to here as common EGFR mutations (cEGFR),
constitute approximately 80% to 90% of all EGFR mutations.[7–9]
Clinical trials of the first-generation EGFR TKIs gefitinib and erlotinib
[2,3,10–13] and second-generation EGFR TKI afatinib [4–6] in patients
with advanced NSCLC harboring cEGFR have shown a median PFS
ranging from 8.0 to 13.6 months and a median OS ranging from 19.3 to
33.3 months. Recent results from the FLAURA study assessing the thirdgeneration EGFR TKI osimertinib in patients with cEGFR demonstrated a
median PFS of 18.9 months and a median OS of 38.6 months.[14,15]
In contrast, EGFR exon 20 insertion mutations (exon20ins), which
comprise up to 12% of EGFR mutations in patients with NSCLC,[7–9]
have not been extensively studied, and the available information on
treatment efficacy is relatively sparse due to the exclusion of patients
with EGFR exon20ins from large EGFR TKI trials. Patients with EGFR
exon20ins exhibit primary resistance to currently available EGFR TKIs
and face poor clinical outcomes.[16,17] A recent retrospective case se
ries study assessing first-line EGFR TKI therapy in patients with EGFR
exon20ins demonstrated a median OS of 16.8 months,[18] which is
approximately half of 31.6 months reported in patients with cEGFR
treated with afatinib in the LUX-Lung 3 study.[6] In a pooled analysis of
the LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 studies in patients with
EGFR exon20ins, frontline afatinib resulted in a median OS of 9.2 months
and a median PFS of 2.7 months.[19] Treatment with the firstgeneration EGFR TKIs as second-line therapy has also been shown in a
prospective observational study to produce similarly poor outcomes in
patients with EGFR exon20ins—a median OS of 12.9 months and a me
dian PFS of 1.9 months.[20] Second-line afatinib similarly resulted in a
median time to treatment failure of 3.6 months in patients with EGFR
exon20ins.[21] Real-world data from the US Flatiron electronic health
record database showed that second-line treatment in patients with
EGFR exon20ins was associated with a median PFS of only 3.7 months.
[22] However, emergent targeted therapies may improve outcomes in
this population. Preliminary data from the EGFR exon20ins-specific TKIs,
poziotinib and CLN-081, showed overall response rates (ORRs) of 15%
and 40%, respectively, in the post-platinum setting.[23,24] Response to
standard doses of osimertinib has also been reported, although in a
limited number of patients.[25,26] Notably, amivantamab, an EGFRMET bispecific antibody, which demonstrated an ORR of 40% and a
median duration of response of 11.1 months, was recently granted
accelerated approval by the US Food and Drug Administration (FDA;
May 2021) for adult patients with locally advanced or metastatic NSCLC
with exon20ins whose disease has progressed on or after platinum-based
chemotherapy.[27,28] Mobocertinib, an EGFR exon20ins-specific TKI,
was also granted US FDA approval for the same patient population.[29]
Patients with EGFR exon20ins were often excluded from phase 3
trials of the now-approved EGFR TKIs. As a result, the natural history,
treatment patterns, and clinical outcomes in these patients are not well
characterized. Furthermore, to our knowledge, outcomes in patients
with EGFR exon20ins have not been directly compared with those with
cEGFR in a real-world setting. We undertook this real-word evidence
analysis to assess 1) the prognostic value of EGFR exon20ins compared
with cEGFR in patients with advanced NSCLC, 2) the predictive value of
EGFR TKI therapy for clinical benefit in EGFR exon20ins compared with
cEGFR, and 3) real-world patient characteristics, treatment patterns, and
clinical outcomes of patients with EGFR exon20ins.

2.1. Study design and patients
The Flatiron Health database is a nationwide longitudinal, demo
graphically and geographically diverse de-identified database derived
from electronic health record (EHR) data from over 280 cancer clinics
(~800 sites of care) including more than 2.4 million US cancer patients
available for analysis. The de-identified patient-level data in the EHRs
include structured data (eg, laboratory values and prescribed drugs) and
unstructured data collected via technology-enabled chart abstraction
from physician’s notes and other unstructured documents (eg,
biomarker reports). These data were used to generate an advanced
NSCLC-specific, subscription-based real-world dataset that enables re
searchers to monitor and analyze key aspects of the patient journey. The
dataset delivers a wide pool of clinical data, including patient de
mographics, treatment, and clinical outcomes.
This retrospective cohort study included de-identified adult patients
(aged ≥ 18 years) of either sex in the advanced NSCLC Flatiron registry
EHR database between January 1, 2011 and May 31, 2020. The data
were obtained through a license agreement. Other key eligibility criteria
were 1) confirmed diagnosis of advanced NSCLC (stage IIIB, IIIC, IVA, or
IVB) or early-stage NSCLC with subsequent recurrent or progressive
disease, with at least 2 documented clinical visits during the study
period, 2) start of first-line therapy within 90 days following advanced
NSCLC diagnosis, 3) structured activity (eg, office visit, medication fill)
within 90 days following advanced NSCLC diagnosis, and 4) positive test
result for EGFR exon20ins or cEGFR before or up to 28 days after the
index date. Patients with both EGFR exon20ins and cEGFR mutations
were excluded.
For the prognostic value analysis, the start date of the first-line
treatment was the index date; for the predictive value analysis, the
start date of a line of the first EGFR TKI treatment was the index date.
Real-world patient characteristics, treatment patterns, and clinical out
comes in patients with EGFR exon20ins were evaluated at first-line
(treatment naive) and second-line (relapsed/refractory) therapy, and
the start date of the first- and second-line treatment, respectively, was
the index date. The availability of the patient chart in the EHR for all
patients treated in the Flatiron network allowed a longitudinal follow-up
of eligible patients. Because only data from de-identified patient health
records were used, and no individually identifiable data were collected,
used, or transmitted, approval from an Institutional Review Board (IRB)
and informed patient consent were not required. Flatiron Health has a
master research parent protocol that has been approved by the IRB of
record for Flatiron Health, and a waiver has been obtained for informed
consent and Health Insurance Portability and Accountability Act
authorization based on minimal risk research.
2.2. Study endpoints
Prognostic value is a measurement of the natural history of disease,
agnostic of the therapies provided. The prognostic value of EGFR exo
n20ins was assessed by comparing real-world OS (rwOS; primary
endpoint) in patients with EGFR exon20ins vs cEGFR. As part of a
sensitivity analysis, rwOS estimates were also examined using the date
of advanced diagnosis instead of start date of first-line therapy as index
date.
A biomarker is predictive when its presence or absence is correlated
with response to a particular treatment. For the purposes of this analysis,
predictive value of EGFR exon20ins was assessed by comparing realworld PFS (rwPFS; primary endpoint) in patients with EGFR exon20ins
vs cEGFR who received EGFR TKI therapy. To account for any differ
ences in timing of EGFR TKI use in the 2 cohorts, the analysis was
stratified by line of therapy when TKI was initiated. Furthermore, the
impact of using first-, second-, or third-generation EGFR TKI was eval
uated in a sensitivity analysis.
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index date (start date of the first EGFR TKI treatment line for the pre
dictive value analysis) to the first episode of disease progression or
death; rwTTNT was defined as the time from the index date to the start
date of the next line of therapy or death, censoring at the last activity
date for patients without a next line of therapy and not known to be
dead.
Statistical analyses were performed using SAS v9.4 (SAS Institute
Inc., Cary, NC, USA). The endpoints of rwOS, rwPFS, and rwTTNT were
summarized using Kaplan–Meier estimates for each cohort, including
median and quartiles of survival with 95% CIs. For the prognostic value
analysis, adjusted hazard ratio (HR), its 95% CI, and p values were
calculated using multivariable Cox proportional hazards model,
including the covariates of age, time from diagnosis of advanced disease
to treatment, time from initial to advanced diagnosis, line of therapy,
Eastern Cooperative Oncology Group performance status (ECOG PS),
smoking history, sex, and practice type (community/academic). For the
predictive value analysis, the EGFR TKI line of therapy was used as
stratum, in addition to the covariates used in the Cox model for the

Secondary endpoints were rwPFS and real-world time to next ther
apy (rwTTNT) for the prognostic value analysis and rwOS and rwTTNT
for the predictive value analysis.
2.3. Data conventions and statistical analysis
Real-world OS was defined as the time from index date (start date of
first-line therapy) to death. The start date of first-line therapy was
chosen instead of date of advanced disease diagnosis because most pa
tients by the start date of first-line therapy have their biomarker tests
available, which helps avoid potential bias of immortal time (time from
the date of advanced diagnosis to date of biomarker test during which a
death event cannot be observed). Due to privacy regulations, only month
and year of death were available; therefore, for patients with a month
and year of death, 15th day of the month or the day following the last
confirmed activity date, whichever was later, was considered the date of
death. Patients without a death date were treated as censored at the last
confirmed activity date. Real-world PFS was defined as the time from

Fig. 1. Patient disposition for treatment lines 1–3 and study populations. cEGFR, common EGFR mutations; EGFR, epidermal growth factor receptor; exon20ins, EGFR
exon 20 insertions; TKI, tyrosine kinase inhibitor.
156

L. Bazhenova et al.

Lung Cancer 162 (2021) 154–161

prognostic value analysis. Patient characteristics, treatment patterns,
and clinical outcomes for patients with EGFR exon20ins were reported
using descriptive statistics.
From prior experience with the Flatiron database, it was anticipated
that ECOG PS would not have been systematically captured for every
patient included in this analysis. Covariate adjusted analyses handled
missing values in 2 ways. The primary method considered missing
values as another category for a categorical covariate. For a sensitivity
analysis, missing values of a categorical covariate were imputed with the
mode of non-missing values of this covariate. A sensitivity analysis on a
subgroup of patients with an index year between 2015 and 2020 was
conducted to allow for increasing availability of ECOG PS through this
period for both prognostic value and predictive analyses. In addition,
EGFR exon20ins and cEGFR identified at any time were included with
delayed entry model (left truncation) as a sensitivity analysis for rwOS.

Table 1
Demographic and Baseline Clinical Characteristics.
Characteristic

Prognostic Value Analysis

Predictive Value Analysis

cEGFR
(N =
2833)

Exon20ins
(N = 181)

cEGFR
(N =
2749)

Exon20ins
(N = 76)

Line of EGFR TKI therapy, n (%)
1
NA

NA

43 (56.6)

2

NA

NA

≥3
Age, Mean (SD), years

NA
68.0
(10.7)
1895
(66.9)

NA
66.0 (10.3)

2239
(81.4)
431
(15.7)
79 (2.9)
68.0
(10.6)
1842
(67.0)

1603
(56.6)
379
(13.4)
205 (7.2)

109 (60.2)

1554
(56.5)
374
(13.6)
203 (7.4)

47 (61.8)

6 (0.2)
335
(11.8)
305
(10.8)

1 (0.6)
23 (12.7)

6 (0.2)
317
(11.5)
295
(10.7)

1 (1.3)
7 (9.2)

146 (5.2)
2687
(94.8)

9 (5.0)
172 (95.0)

146 (5.3)
2603
(94.7)

4 (5.3)
72 (94.7)

1327
(46.8)
292
(10.3)
1214
(42.9)

96 (53.0)

1246
(45.3)
296
(10.8)
1207
(43.9)

33 (43.4)

2741
(96.8)
40 (1.4)
52 (1.8)

174 (96.1)

2660
(96.8)
37 (1.3)
52 (1.9)

76 (100.0)

164 (6.0)
86 (3.1)
171 (6.2)
101 (3.7)
2177
(79.2)
50 (1.8)

6 (7.9)
3 (3.9)
5 (6.6)
2 (2.6)
59 (77.6)

1220
(44.4)
1518
(55.2)
11 (0.4)

37 (48.7)

2445
(88.9)
304
(11.1)
2.6
(5.52)

67 (88.2)

4.7
(14.86)

6.5 (18.01)

Female, n (%)
Race, n (%)
White

3. Results

Asian

3.1. Patient disposition and baseline characteristics

Black or African
American
Hispanic or Latino
Other

Among 62,464 patients with advanced NSCLC in the Flatiron registry
database, 38,928 had EGFR mutations tested, of which 4485 (11.5%)
had either cEGFR or EGFR exon20ins, detected primarily by nextgeneration sequencing or polymerase chain reaction. Of these, 3272
patients had structured activity (eg, office visit, medication fill) within
90 days following diagnosis, had received first-line therapy within 90
days following diagnosis, and had cEGFR (n = 3061 [93.6%]) or EGFR
exon20ins (n = 211 [6.4%]) (Fig. 1). For prognostic value analysis, 3014
patients (cEGFR, 2833; EGFR exon20ins, 181) met all study criteria and
had an EGFR mutation detected before or up to 28 days after the start of
treatment; the corresponding numbers were 1744 patients for secondline therapy (cEGFR, 1629; EGFR exon20ins, 115) and 949 patients for
third-line therapy (cEGFR, 885; EGFR exon20ins, 64). For predictive
value analysis, 2825 patients (cEGFR, 2749; EGFR exon20ins, 76) had an
EGFR mutation detected before or up to 28 days after the start of first
EGFR TKI line of therapy. The demographic and baseline clinical char
acteristics were generally balanced between the cEGFR and EGFR exo
n20ins cohorts in both prognostic and predictive analyses populations
(Table 1).

Unknown
Ethnicity, n (%)
Hispanic
Unknown
ECOG PS, n (%)
≤1
≥2
Unknown
Histology, n (%)
Non-squamous
Squamous
NSCLC histology NOS

Group stage at initial diagnosis, n (%)
Stage I
176 (6.2)
Stage II
93 (3.3)
Stage III
178 (6.3)
Stage IIIB/C
103 (3.6)
Stage IV
2229
(78.7)
Unknown
54 (1.9)

3.2. Prognostic value of EGFR Exon20ins vs cEGFR
Among 3014 patients eligible for prognostic value analysis, 2833 had
cEGFR and 181 had exon20ins. Overall, 114 patients (63.0%) died in the
EGFR exon20ins cohort compared with 1575 (55.6%) in the cEGFR
cohort. The median rwOS was 16.2 months (95% CI, 11.04–19.38
months) in the EGFR exon20ins cohort compared with 25.5
(24.48–27.04) months in the cEGFR cohort (adjusted HR, 1.75
[1.45–2.13]; p < 0.0001) (Fig. 2A; Supplementary Table 1). The 5-year
rwOS rate was 8% in the EGFR exon20ins cohort compared with 19% in
the cEGFR cohort.
The sensitivity analysis for the primary endpoint rwOS and subgroup
analyses are shown in Supplementary Fig. 1. Consistent with the primary
analysis, the sensitivity analysis that used ECOG PS ≤ 1 as category for
missing ECOG PS and the one that used index year ≥ 2015 showed that
patients with exon20ins had worse prognosis compared with those with
cEGFR. The subgroup analyses for missing ECOG PS and ECOG PS ≤ 1
showed similar results. In addition, the sensitivity analysis that calcu
lated rwOS from the date of advanced diagnosis instead of start of firstline therapy resulted in approximately 1-month longer median OS for
both cohorts, but the HRs and CIs were similar to those from the primary
analysis. The primary analysis excluded 30 patients with exon20ins and
228 with cEGFR who had their mutation detected more than 28 days
after start of first-line therapy. To assess the effect of including these
patients on prognostic value of exon20ins, a delayed entry Cox propor
tional hazards model was used; the model showed that including these

Smoking history, n (%)
Yes
No
Unknown
Practice type, n (%)
Community
Academic
Time from advanced
diagnosis to
treatment, mean (SD),
months
Time from initial to
advanced diagnosis,
mean (SD), months

111 (61.3)

11 (6.1)
17 (9.4)

20 (11.0)

13 (7.2)
72 (39.8)

5 (2.8)
2 (1.1)
12 (6.6)
8 (4.4)
11 (6.1)
8 (4.4)
140 (77.3)
2 (1.1)

1271
(44.9)
1550
(54.7)
12 (0.4)

97 (53.6)

2532
(89.4)
301
(10.6)
1.1
(0.65)

161 (89.0)

4.9
(15.24)

6.6 (19.45)

84 (46.4)
0

20 (11.0)
1.1 (0.62)

19 (25.0)
14 (18.4)
68.7 (9.0)
43 (56.6)

8 (10.5)
5 (6.6)

8 (10.5)

8 (10.5)
35 (46.1)

0
0

1 (1.3)

39 (51.3)
0

9 (11.8)
7.0 (10.25)

cEGFR, common EGFR mutations; ECOG PS, Eastern Cooperative Oncology
Group performance status; EGFR, epidermal growth factor receptor; exon20ins,
EGFR exon 20 insertions; NA, not applicable.
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Table 2
Summary of First EGFR TKI Use (TKI Generation and Setting)
Parameter

cEGFR

Exon20ins

First EGFR TKI use (any line), n (%)
Gen 1: Erlotinib or Gefitinib
Gen 2: Afatinib or Dacomitinib
Gen 3: Osimertinib

N = 2749
1515 (55.1)
418 (15.2)
815 (29.6)

N = 76
38 (50.0)
20 (26.3)
18 (23.7)

EGFR TKI on first line, n (%)
Gen 1: Erlotinib or Gefitinib
Gen 2: Afatinib or Dacomitinib
Gen 3: Osimertinib

N = 2238
1243 (55.5)
331 (14.8)
664 (29.7)

N = 43
25 (58.1)
9 (20.9)
9 (20.9)

EGFR TKI on second line, n (%)
Gen 1: Erlotinib or Gefitinib
Gen 2: Afatinib or Dacomitinib
Gen 3: Osimertinib

N = 1134
377 (33.2)
252 (22.2)
505 (44.5)

N = 25
11 (44.0)
7 (28.0)
7 (28.0)

EGFR TKI on third line, n (%)
Gen 1: Erlotinib or Gefitinib
Gen 2: Afatinib or Dacomitinib
Gen 3: Osimertinib

N = 412
131 (31.8)
78 (18.9)
203 (49.3)

N=7
2 (28.6)
1 (14.3)
4 (57.1)

cEGFR, common EGFR mutations; EGFR, epidermal growth factor receptor;
exon20ins, EGFR exon 20 insertions; Gen, generation; TKI, tyrosine kinase
inhibitor.

3.3. Predictive value of EGFR TKI treatment for EGFR Exon20ins vs
cEGFR
The predictive value analysis compared outcomes on the first use of
an EGFR TKI line between patients with cEGFR (n = 2749) or EGFR
exon20ins (n = 76). After a median follow-up period of 20.6 months, 59
events (77.6%) of disease progression or deaths occurred in the EGFR
exon20ins cohort and 1793 (65.2%) in the cEGFR cohort. The median
rwPFS estimate (primary endpoint) was 2.9 months (95% CI, 2.14–3.91
months) in the EGFR exon20ins cohort compared with 10.5
(10.05–10.94) months in cEGFR cohort (adjusted HR, 2.69 [2.05–3.54];
p < 0.0001) (Fig. 2B; Supplementary Table 2). The 1-year rwPFS rate
was 13% in the EGFR exon20ins cohort compared with 43% in the cEGFR
cohort.
Among patients on the first EGFR TKI line, the median rwOS (sec
ondary endpoint) in the EGFR exon20ins cohort (7.5 [5.45–13.34]
months) was significantly shorter compared with that in the cEGFR
cohort (25.5 [24.28–26.81] months) (adjusted HR, 2.70 [2.04–3.57]; p
< 0.0001; Supplementary Table 2). Similarly, the median rwTTNT
(secondary endpoint) was significantly shorter in the EGFR exon20ins
cohort (3.9 [2.86–5.45] months) compared with that in the cEGFR
cohort (12.7 [12.29–13.34] months) (adjusted HR, 2.54 [1.97–3.27]; p
< 0.0001). The predictive value analysis by first-, second-, and thirdgeneration EGFR TKI as first TKI line is presented in Supplementary
Table 3.
The sensitivity analysis for the primary endpoint rwPFS and sub
group analyses are shown in Supplementary Fig. 2. Consistent with the
primary analysis, the sensitivity analysis that used using ECOG PS ≤ 1 as
category for missing ECOG PS and the one that used index year ≥ 2015
subset showed that when treated with EGFR TKIs, patients with exo
n20ins had worse outcomes compared with those with cEGFR. The
subgroup analyses for missing ECOG PS and ECOG PS ≤ 1 showed
similar results. In addition, including another covariate—TKI gen
eration—to the primary analysis produced HRs and CIs that were
approximately the same as those for the primary analysis. The low
number of patients with ECOG PS ≥ 2 in the EGFR exon20ins cohort
made the HR estimate unreliable and resulted in a wide CI.

Fig. 2. rwOS and rwPFS (primary endpoints) estimated by Kaplan-Meier curves
in patients with EGFR exon20ins (red) vs cEGFR (blue). Patients with positive
test results for EGFR exon20ins or cEGFR before or up to 28 days after the index
date were included. HR, hazard ratio; cEGFR, common EGFR mutations; EGFR,
epidermal growth factor receptor; exon20ins, EGFR exon 20 insertions; mITT,
modified intent-to-treat; rwOS, real-world overall survival; rwPFS, real-world
progression-free survival; TKI, tyrosine kinase inhibitor. aAnalysis stratified
by line of treatment. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)

patients did not change the HRs and CIs from the primary analysis. The
low number of patients with ECOG PS ≥ 2 in the EGFR exon20ins cohort
made the HR estimate unreliable and resulted in a wide CI.
In patients with EGFR exon20ins vs cEGFR receiving any first-line
therapy, the secondary endpoints of rwPFS and rwTTNT showed
similar results (Supplementary Table 1). The median rwPFS in the EGFR
exon20ins cohort (5.1 [3.71–6.28] months) was significantly shorter
compared with that in the cEGFR cohort (10.3 [9.92–10.68] months)
(adjusted HR, 1.93 [1.61–2.31]; p < 0.0001). Similarly, the median
rwTTNT in the EGFR exon20ins cohort (6.4 [5.22–8.11]) was signifi
cantly shorter compared with that in the cEGFR cohort (10.8
[10.35–11.30]) (adjusted HR, 1.6 [1.36–1.9]; p < 0.0001).
Approximately half of the patients in both the cEGFR and EGFR
exon20ins cohorts received first-generation EGFR TKIs erlotinib or
gefitinib as their first EGFR TKI treatment (Table 2). There were no
major imbalances in the distribution of EGFR TKI generations across the
comparator populations. Approximately 20% to 30% of patients in both
cohorts received osimertinib.

3.4. Treatment patterns in patients with EGFR Exon20ins
Most patients (61.3%) with EGFR exon20ins were prescribed
platinum-based chemotherapy regimens in the first-line setting, fol
lowed by EGFR TKI monotherapy (21.5%) (Table 3). It is noteworthy
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3.5. Clinical outcomes by therapy type in first and second lines in patients
with EGFR Exon20ins

Table 3
Treatment Patterns in Patients With EGFR Exon 20 insertions.
Treatment, n (%)

First Line (N
= 181)

Second Line (N
= 115)

Third Line
(N = 64)

Platinum based regimen
Platinum doublet
Platinum + EGFR TKI
Platinum + immunotherapy
Platinum + EGFR TKI +
immunotherapy
Platinum + EGFR TKI +
VEGFi
Platinum +
immunotherapy + VEGFi
Platinum + VEGFi
Platinum alone
EGFR TKI alone
EGFR TKI Combinations
Immunotherapy alone
VEGFi alone
Non-platinum chemotherapy
Others

111 (61.3)
50 (27.6)
1 (0.6)
32 (17.7)
1 (0.6)

27 (23.5)
13 (11.3)
0
8 (7.0)
0

14 (21.9)
5 (7.8)
0
2 (3.1)
0

1 (0.6)

0

0

1 (0.6)

0

0

25 (13.8)
0
39 (21.5)
1 (0.6)
16 (8.8)
1 (0.6)
5 (2.8)
8 (4.4)

5 (4.3)
1 (0.9)
25 (21.7)
0
33 (28.7)
11 (9.6)
15 (13.0)
4 (3.5)

7 (10.9)
0
7 (10.9)
0
14 (21.9)
7 (10.9)
19 (29.7)
3 (4.7)

Survival outcomes (rwOS and rwPFS) were assessed in patients with
EGFR exon20ins receiving different therapies in first and second lines.
Across all therapies in the frontline setting, the median rwOS was 16.2
months, and the median PFS was 5.1 months (Fig. 3). In the second-line
setting across all therapies, the median rwOS was 13.3 months, and the
median PFS was 3.2 months. Platinum-based chemotherapy was asso
ciated with the longest median rwOS (first line, 17.4 months; second
line, 14.2 months) and rwPFS (6.6 and 5.0 months, respectively). The
survival outcomes in the second-line setting were heterogeneous across
treatments and generally poor; the median rwPFS estimates were
notably poor, ranging from 2.3 to 5.2 months.
4. Discussion
In this retrospective real-world cohort study, we found that patients
with NSCLC harboring EGFR exon20ins had a significantly worse prog
nosis compared with those having cEGFR mutations. Across all frontline
treatments, the risk of death was 75% higher (adjusted HR, 1.75; see
Fig. 2A and Supplementary Table 1) and the risk of disease progression
or death was 93% higher (adjusted HR, 1.93; see Supplementary Table
1) in patients with EGFR exon20ins vs cEGFR. Similarly, the predictive
value analysis showed that after initiating EGFR TKI treatment, patients
with EGFR exon20ins experienced significantly inferior outcomes
compared with those with cEGFR; the risk of progression or death
increased by 169% (adjusted HR, 2.69; see Fig. 2B and Supplementary
Table 2) and that of death increased by 170% (adjusted HR, 2.70; see

EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; VEGFi,
vascular endothelial growth factor inhibitor.

that 21.5% of patients did receive first-line EGFR TKIs. In the secondand third-line setting, several different therapies were used, including
immunotherapy, EGFR TKI monotherapy, platinum-based regimens,
and non-platinum chemotherapy. The treatment patterns in patients
with cEGFR are shown in Supplementary Table 4.

Fig. 3. Clinical outcomes (median ± 95% CI) by therapy type in first and second lines in patients with EGFR exon20ins. The IO alone real-world OS data (first- and
second-line therapy) and platinum + IO real-world PFS data (second-line therapy) did not have the upper bound of its 95% CI. EGFR, epidermal growth factor
receptor; exon20ins, EGFR exon 20 insertions; IO, immunotherapy; NE, not estimable; OS, overall survival; PFS, progression-free survival; TKI, tyrosine ki
nase inhibitor.
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Supplementary Table 2). Our findings are consistent with other realworld studies showing poor outcomes for patients with EGFR exo
n20ins.[22,30,31]
Assessment of treatment patterns demonstrated heterogeneity in
second-line treatments, with poor outcomes across all treatments,
especially rwPFS (average across treatments was 3.2 months). Despite
the known lack of efficacy of EGFR TKI in patients with EGFR exon20ins
NSCLC, TKI monotherapy was given in the frontline setting in 21.5% of
patients in the real-world setting.
The rwPFS and rwOS outcomes with EGFR TKI therapy in patients
with cEGFR in the present study are consistent with those from phase 3
trials assessing outcomes with first- and second-generation EGFR TKIs,
[3–6,10–12] which were the predominant EGFR TKIs utilized in this
database. Third-generation EGFR TKIs (eg, osimertinib) were developed
to target the EGFR T790M mutation that is responsible for acquired
resistance to first- and second-generation EGFR TKIs.[32] First-line
treatment with osimertinib has shown improved median OS compared
with first-generation EGFR TKIs (38.6 vs 31.8 months) in patients with
cEGFR mutations.[14] Frontline use of osimertinib was approved for the
treatment of NSCLC with cEGFR in April 2018,[33] indicating that most
patients in the present study, which included data from 2011 through
May 2020, were unlikely to have received this drug. However, 20% to
30% of patients in the present study did receive osimertinib, suggesting
its prevalent use post approval and that the difference in outcomes be
tween EGFR exon20ins and cEGFR cohorts observed here could further
increase as osimertinib continues to be prescribed in the first-line setting
to patients with cEGFR.
Analyses involving EHR data, such as the Flatiron database, are
associated with certain limitations. Flatiron data are generated from
real-world clinical practice settings and, therefore, are subject to missing
data or data entry errors. In addition, information about treatment
outside of the specific cancer care sites may not have been captured.
Similarly, information about patients prior to the adoption of EHRs may
not have been included. Treatment regimens for the patients included in
this database were determined by physicians’ discretion based on many
confounding factors that may be unaccounted for, limiting the inter
pretability of the predictive analysis. Ultimately, exon20ins are highly
diverse, which may bring heterogeneity in the efficacy of available op
tions; one example is the FQEA insertions that may predict response to
EGFR TKIs.[34,35]
Generalizability of the analysis is limited by multiple factors. For
example, the advanced NSCLC Flatiron registry database mostly in
cludes patients treated at community oncology clinics, and patients not
seeking systemic treatment or treated outside the Flatiron network could
have different outcomes. Informative censoring (eg, sicker patients
leaving the database and potentially missing death data) may bias es
timates of survival, limiting ability to compare OS estimates with those
from other data sources. One covariate—ECOG PS—had a large amount
of missingness (40%-46%) in this study, which could have introduced
bias; however, the rate of missingness was similar between the 2 cohorts.
It was assumed that the missingness of ECOG PS was random. Further
more, the sensitivity analyses that used ECOG PS ≤ 1 for missing ECOG
PS produced results that were consistent with primary analyses.
In conclusion, the results of this retrospective real-world cohort
study show that patients with EGFR exon20ins have poorer prognosis
than those with cEGFR, with 5-year rwOS of 8% and 19%, respectively.
Patients with EGFR exon20ins receive little benefit from EGFR TKI
treatment, have no standard of care in the second-line setting, and are in
urgent need of new treatment options. Two new therapies,
amivantamab—a bispecific antibody against EGFR and MET receptor—
and mobocertinib—an EGFR exon20ins-specific TKI—both recently
received accelerated approval for adult patients with locally advanced
or metastatic NSCLC with EGFR exon20ins whose disease has progressed
on or after platinum-based chemotherapy.[27,29]
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